I agree that this site is using cookies. You can find further informations here.
X
Hurley, Rachel M
~ 3300  results:
Search for persons X
?
1

A phase 1 and pharmacodynamic study of chronically-dosed, s..:

Manzo, Julia ; Puhalla, Shannon ; Pahuja, Shalu...
Cancer Chemotherapy and Pharmacology.  89 (2022)  5 - p. 721-735 , 2022
Link: https://doi.org/10.1007/..
 
?
2

Characterization of a RAD51C-silenced high-grade serous ova..:

Hurley, Rachel M ; McGehee, Cordelia D ; Nesic, Ksenija...
NAR Cancer.  3 (2021)  3 - p. , 2021
Link: https://doi.org/10.1093/..
 
?
3

Statistical analysis of comparative tumor growth repeated m..:

Oberg, Ann L. ; Heinzen, Ethan P. ; Hou, Xiaonan...
Scientific Reports.  11 (2021)  1 - p. , 2021
Link: https://doi.org/10.1038/..
 
?
4

CHFR and Paclitaxel Sensitivity of Ovarian Cancer:

Wahner Hendrickson, Andrea E. ; Visscher, Daniel W. ; Hou, Xiaonan...
Cancers.  13 (2021)  23 - p. 6043 , 2021
Link: https://doi.org/10.3390/..
 
?
5

53BP1 as a potential predictor of response in PARP inhibito..:

Hurley, Rachel M. ; Wahner Hendrickson, Andrea E. ; Visscher, Daniel W....
Gynecologic Oncology.  153 (2019)  1 - p. 127-134 , 2019
Link: https://doi.org/10.1016/..
 
?
6

In vivo anti-tumor activity of the PARP inhibitor niraparib..:

AlHilli, Mariam M. ; Becker, Marc A. ; Weroha, S. John...
Gynecologic Oncology.  143 (2016)  2 - p. 379-388 , 2016
Link: https://doi.org/10.1016/..
 
?
7

132 Attenuation of Pancreatic Cancer Metastasis Through Spe..:

Razidlo, Gina L. ; Magnine, Christopher ; Sletten, Arthur C....
Gastroenterology.  148 (2015)  4 - p. S-34 , 2015
Link: https://doi.org/10.1016/..
 
?
8

Tu1686 Attenuation of Pancreatic Cancer Cell Migration and ..:

Razidlo, Gina L. ; Magnine, Christopher ; Sletten, Arthur C...
Gastroenterology.  146 (2014)  5 - p. S-818-S-819 , 2014
Link: https://doi.org/10.1016/..
 
?
9

The Elephant and the Blind Men: Making Sense of PARP Inhibi..:

De Lorenzo, Silvana B. ; Patel, Anand G. ; Hurley, Rachel M..
Frontiers in Oncology.  3 (2013)  - p. , 2013
Link: https://doi.org/10.3389/..
 
?
10

A Phase 1 and Pharmacodynamic Study of Chronically-Dosed, S..:

Manzo, Julia ; Puhalla, Shannon ; Pahuja, Shalu...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116722/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

Hereditary Thrombotic Thrombocytopenic Purpura in a 9-Month..:

Wyatt, Kirk D ; Kohorst, Mira A ; Coon, Lea M...
https://boris.unibe.ch/150908/.  , 2021
Link: https://boris.unibe.ch/1..
 
?
12

Characterization of a RAD51C-silenced high-grade serous ova..:

Hurley, Rachel M ; McGehee, Cordelia D ; Nesic, Ksenija...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271218/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
13

Statistical analysis of comparative tumor growth repeated m..:

Oberg, Ann L ; Heinzen, Ethan P ; Hou, Xiaonan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044116/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
14

53BP1 as a Potential Predictor of Response in PARP Inhibito..:

Hurley, Rachel M ; Hendrickson, Andrea E. Wahner ; Visscher, Daniel W...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430710/.  , 2019
Link: http://www.ncbi.nlm.nih...
 
?
15

53BP1 as a potential predictor of response in PARP inhibito..:

Hurley, Rachel M ; Hendrickson, Andrea E. Wahner ; Visscher, Daniel W...
Hurley , R M , Hendrickson , A E W , Visscher , D W , Ansel , P , Harrell , M I , Wagner , J M , Negron , V , Goergen , K M , Maurer , M J , Oberg , A L , Meng , X W , Flatten , K S , De Jonge , M J A , Van Herpen , C D , Gietema , J A , Koornstra , R H T , Jager , A , den Hollander , M W , Dudley , M , Shepherd , S P , Swisher , E M & Kaufmann , S H 2019 , ' 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer ' , Gynecologic Oncology , vol. 153 , no. 1 , pp. 127-134 . https://doi.org/10.1016/j.ygyno.2019.01.015 ; ISSN:0090-8258.  , 2019
Link: http://hdl.handle.net/11..
 
1-15